Lesage Anne sold $1.1M of PHVS

Lesage Anne (Chief Early Development) sold 30,000 shares of Pharvaris N.V. (PHVS) at $38.30 ($1.15M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lesage Anne
Published Sep 14, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, potentially influencing short-term price action.

02

Market read

New insider sale may prompt traders to reassess PHVS's short-term outlook.

03

What to watch

Insider's 10b5-1 plan pre-arranged the sale, reducing informational value.

Relevance 5/10Novelty 8/10Timing: filing today

Background

SEC Form 4 filing reports an insider transaction for Pharvaris.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Chief Early Development officer Lesage Anne sold 30,000 shares of Pharvaris (PHVS) for $1.149M on Sep 10, 2026.

Expected impact

Possible short-term dip of 2-3% as market digests the sale.

Evidence & confidence

Officer-level insider sold a sizable block, indicating possible concerns, but the amount is modest relative to market cap.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. biotech investors.

Low global relevance.

Counterpoint

The sale may be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Lesage Anne

    Chief Early Development officer at Pharvaris

  • Pharvaris N.V.

    Biotech company listed on Nasdaq under PHVS

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.